Way overbought!Not a fan of shorting low volume pharmaceuticals and bio, this one has gone up too fast on Covid. Looking for a pullback under $6 in the next two weeks
Key stats
Market capitalization
42.67MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.3370USD
About Eiger BioPharmaceuticals, Inc
ISIN
US28249U1051
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
eigerbio.com
CEO
David Apelian
Headquarters
Palo Alto
Employees
56
Founded
2008
Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Eiger Announces FDA Breakthrough Therapy Designation for AvexitiEIGR: Eiger BioPharmaceuticals, Inc.
2021-08-05 08:00:00
Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism
EIGR BULLISH BATX-B is retrace is slightly over target. That said this has an average analyst target of $34.17. It looks like it will be dropping for a little bit. So wait on entry
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 EIGR: Eiger BioPharmaceuticals, Inc.
2018-10-16 16:05:00
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
EIGR Support Line Push-UpEIGR just rose $2.50 over a 1 week period. It now seems like it could see another big push up with a support line push from above it's position right now
See all ideas
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0